Author/Authors :
Akbari, Abolfazl tehran university of medical sciences tums - School of Advanced Medical Technologies - Department of Molecular Medicine, تهران, ايران , Amanpour, Saeid tehran university of medical sciences tums - Cancer Institute of Iran, Cancer Research Center, تهران, ايران , Muhammadnejad, Samad tehran university of medical sciences tums - Cancer Institute of Iran, Cancer Research Center, تهران, ايران , Ghahremani, Mohammad Hossein tehran university of medical sciences tums - School of Advanced Medical Technologies, Faculty of Pharmacy - Department of Molecular Medicine, Department of Pharmacology and Toxicology, تهران, ايران , Ghaffari, Hamidollah tehran university of medical sciences tums - Shariati Hospital, Hematology, Oncology and Stem Cell Transplantation Research Center, تهران, ايران , Dehpour, Ahmad Reza tehran university of medical sciences tums - School of Medicine - Department of Pharmacology, تهران, ايران , Mobini, Gholam Reza tehran university of medical sciences tums - School of Advanced Medical Technologies - Department of Molecular Medicine, تهران, ايران , Shidfar, Fatemeh tehran university of medical sciences tums - School of Advanced Medical Technologies - Department of Molecular Medicine, تهران, ايران , Abastabar, Mahdi mazandaran university of medical sciences - School of Medicine, Invasive Fungi Research Center - Department of Medical Mycology and Parasitology, ايران , Khoshzaban, Ahad tehran university of medical sciences tums - Farabi Eye Hospital - Stem Cell Preparation Unit, تهران, ايران , Faghihloo, Ebrahim tehran university of medical sciences tums - School of Public Health - Department of Virology, تهران, ايران , Karimi, Abbas iran university of medical sciences - Faculty of Advanced Technologies in Medicine (FATiM) - Department of Molecular Medicine, ايران , Heidari, Mansour tehran university of medical sciences tums - School of Medicine, Farabi Eye Hospital - Department of Medical Genetics, Stem Cell Preparation Unit, تهران, ايران
Abstract :
Background: Transforming growth factor-β (TGF-β) pathway is involved in primary tumor progression and in promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore, blockage of TGF-β pathway signaling via an inhibitor could be a valuable tool in CRC treatment. Methods: To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by methyl thiazolyl tetrazolium (MTT) and bromo-2′-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers were stained, respectively. Results: Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70, P 0.05) in treated SW-48 cells with SD-208 compared to controls. Conclusion: Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human colorectal cancer model at least using SW-48 cells.
